A Study of Patients Receiving High-Dose Rate Brachytherapy
-
- STATUS
- Recruiting
-
- End date
- Nov 1, 2025
-
- participants needed
- 112
-
- sponsor
- National Cancer Institute (NCI)
Summary
- Background
-
- One standard way of giving radiation is to combine external beam treatments with internal brachytherapy treatments, which involve short-range radiation therapy that gives a high dose of radiation directly to a cancer or to the area where cancer cells were removed.
- Brachytherapy is done by placing hollow implant device(s) into the area to be treated
and then moving a radiation source into each. The type of device depends on the type of
cancer and the site to be treated. These devices can range from hollow applicators and
needles to balloon-like equipment.
- Objectives
- To evaluate the quality of the brachytherapy procedure at the National Institutes of
Health s Radiation Oncology Branch.
- Eligibility
- Patients with cancer who could potentially benefit from high-dose brachytherapy as part
of their treatment.
- Design
- In conjunction with their existing treatment, patients will be treated with high-dose brachytherapy as determined appropriate for their particular type of cancer and cancer history.
- Each treatment will take place in the Radiation Oncology Clinic.
- If the patient does not have implant devices, the clinic staff will insert them and check their placement through a computed tomography (CT) scan.
- The calculations to determine the appropriate brachytherapy dose will take a few hours; the brachytherapy treatment itself will take between 10 and 30 minutes.
- The number of brachytherapy treatments will vary according to the individual needs and requirements of each type of cancer and each patient.
- Patients will return to the Radiation Oncology Clinic for followup visits at 1, 3, 6, 9, and 12 months after the completion of radiation therapy. Followup evaluations will include a medical history and physical examination, assessment of any side effects of radiation therapy, and a repeat of any imaging (i.e., CT, MRI, X-ray) that was done at baseline to evaluate the tumor response.
Description
- BACKGROUND
-
- High dose rate brachytherapy (HDR) is a challenging technique utilized in many malignancies in order to deliver a high dose of radiation therapy to a tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue
- HDR therapy has been targeted to particular subsites as an integral part of either
definitive management or palliation for malignancy-related symptoms.
- OBJECTIVES
- The primary objective is to determine the quality of high dose rate brachytherapy implants performed in the radiation oncology branch. An implant will be adequate if 90% of the GTV receives 90% of the dose prescribed and 80% of the CTV receives 85% of the prescribed dose. An implant will be inadequate if the above dose limitations are not met.
- To evaluate local control and late toxicity rates following brachytherapy at the NCI ROB
- To increase the flow of oncology participants requiring brachytherapy to the NCI ROB, as
these participants lend themselves to special study and have unique educational value
for the purpose of educating nurses, medical students, residents, physicists, clinical
fellows, and physicians.
- ELIGIBILITY
-Participants with cancer who could potentially benefit from the use of high dose rate brachytherapy as a component of their treatment.
- DESIGN
-
- Participants will undergo appropriate work-up and clinical evaluation to determine if high-dose brachytherapy would be beneficial in either primary treatment or palliation of their disease. Participants will be treated with high-dose brachytherapy appropriately sequenced with other modalities in their treatment regimen. This treatment will be administered in accordance with standard radiation oncology practice and per the ABS (American Brachytherapy Society) guidelines.
- The participant s disease status and toxicity outcomes will be documented for a 12-month period at 3-months intervals.
Details
| Condition | Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer |
|---|---|
| Treatment | brachytherapy, HDR Brachytherapy |
| Clinical Study Identifier | NCT00924027 |
| Sponsor | National Cancer Institute (NCI) |
| Last Modified on | 25 July 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer